Trump announces emergency authorization for treating COVID-19 patients
Category: #health  By Pankaj Singh  Date: 2020-08-25
  • share
  • Twitter
  • Facebook
  • LinkedIn

Trump announces emergency authorization for treating COVID-19 patients

U.S. President Donald Trump has reportedly announced emergency authorization for the use of convalescent plasma in the treatment of COVID-19. While Trump reportedly regarded the move to be a breakthrough, one of his top health officials described it as promising and other health experts asserted that the declaration requires more study before moving towards celebration.

The announcement follows a complaint from White House officials who stated that the Food and Drug Administration was witnessing politically motivated delays in the approval of a COVID-19 vaccine that has upended the chances of Trump’s reelection.

According to Denise Hinton, the Chief Scientist for the Food and Drug Administration, COVID-19 convalescent plasma should not be contemplated as a new benchmark of care for the treatment of COVID-19 patients. He has also stated that additional data will be coming from the ongoing clinical trials and other analyses in the ensuing months.

Even though the authorization has made it easier for some patients to receive the treatment, it is not exactly similar to full FDA approval, state sources. The blood plasma taken from patients who have recovered from the disease may deliver benefits to those struggling against COVID-19. The evidence so far has, however, not yet concluded whether it really works, when it should be administered, and what amount of dosage is required.

The pace of plasma approval had left the White House agitated, as per sources. The accusations of an FDA slowdown were presented without evidence and are cited as the recent assault from Trump’s team on what the president calls deep state bureaucracy. Mark Meadows, the White House Chief of Staff, has asserted that several people are not being as meticulous as they ought to be while getting to the bottom of the process.

The White House has sunk extensive resources into an expedited process for developing a COVID-19 vaccine. Trump advisors have been banking on it for helping the president gain ground in the upcoming elections, state sources.

 

Source Credits:

https://abcnews.go.com/Health/wireStory/trump-pushes-covid-19-treatments-claims-slowdown-fda-72555038



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

GENFIT & LabCorp Come Together to Develop a Diagnostic Test for NASH
GENFIT & LabCorp Come Together to Develop a Diagnostic Test for NASH
By Pankaj Singh

GENFIT, a biopharmaceutical company committed to improving the lives of patients suffering from liver and metabolic diseases, and LabCorp®, a leading life sciences enterprise focuses on guiding patient care decisio...

RADLogics obtains FDA's approval for AI-based chest X-Ray App
RADLogics obtains FDA's approval for AI-based chest X-Ray App
By Pankaj Singh

RADLogics Inc., a healthcare software company developing AI-powered solutions has reportedly received 510(k) clearance from the US FDA (Food and Drug Administration) for its latest AI-Powered chest X-ray pneumothorax a...

CDE of China NMPA clears I-Mab’s application for lemzoparlimab
CDE of China NMPA clears I-Mab’s application for lemzoparlimab
By Pankaj Singh

Clinical stage biopharmaceutical major, I-Mab, has reportedly announced that it has received the clearance of the Center for Drug Evaluation of the China National Medical Products Administration for its IND application...